| Product Description | Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow. |
|---|---|
| Form | Liquid |
| Host Species | Human |
| Clonality | Monoclonal |
| Isotype | IgG4-kappa |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Concentration | 1.59mg/ml |
| Endotoxin Level | Please contact the lab for this information. |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Species Reactivity | Human |
| Target | Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolys |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Expression System | Mammalian Cells |
| Accession Number | P61073 |
| Background | Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. • CXCR4 (CD184) expression on stem cell harvest and CD34+ cells post-transplant., PMID:28282510 • CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors., PMID:37375261 • CXCR4 in breast cancer: oncogenic role and therapeutic targeting., PMID:26356032 • CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies., PMID:34298991 • Temporal expression of CD184(CXCR4) and CD171(L1CAM) identifies distinct early developmental stages of human retinal ganglion cells in embryonic stem cell derived retina., PMID:27867005 • Production of human embryonic kidney 293T cells stably expressing C-X-C chemokine receptor type 4 (CXCR4) as a screening tool for anticancer lead compound targeting CXCR4., PMID:35643380 • Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue., PMID:28039356 • Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma., PMID:31882334 • Development of Mimokines, chemokine N terminus-based CXCR4 inhibitors optimized by phage display and rational design., PMID:29570832 • Peptide density targets and impedes triple negative breast cancer metastasis., PMID:29973594 |
| Alternative Names | BMS-936564, MDX-1338, MDX1338, 1375830-34-4 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Product Name | Clicks |
|---|---|
| 痢疾志贺氏菌单克隆抗体 | 7913 |
| 沙门氏菌单克隆抗体 | 7821 |
| 乙型副伤寒沙门氏菌单克隆抗体 | 8243 |
| A族链球菌单克隆抗体 | 7863 |
| 甲型副伤寒沙门氏菌单抗 | 7565 |
| 麻疹病毒单克隆抗体 | 8005 |
| HBeAg单克隆抗体 | 7791 |
| 新型冠状病毒(SARS-COV-2)NP蛋白单克隆抗体 | 7275 |
| 呼吸道腺病毒单克隆抗体 | 8068 |
| 大肠杆菌单克隆抗体 | 8056 |
| LP-PLA2单克隆抗体 | 8058 |
| NT-PROBNP单克隆抗体 | 7729 |
| 半乳糖凝集素3单克隆抗体 | 7667 |
| D二聚体单克隆抗体 | 7713 |
| 肌钙蛋白单克隆抗体 | 7944 |
| 肌红蛋白单克隆抗体 | 7945 |
| AAT单克隆抗体 | 7704 |
| 人SAA单克隆抗体 | 7499 |
| 黏病毒抗性蛋白A单克隆抗体 | 7882 |
| 降钙素原单克隆抗体 | 7488 |